As one of the nation's largest drug distributors, Amerisource Bergen has been an obvious beneficiary of the booming generics business. But the company has quietly become a powerhouse in specialty drugs as well, from which it now generates about 20% of sales. For example, Amerisource commands more than half the community oncologist market, a business expected to see solid growth as baby boomers gray.
No surprise, then, that Steve Collis, a 17-year company veteran -- and the driving force behind Amerisource's specialty drugs unit -- was tapped to take over as CEO when longtime chief David Yost retires in July. --P.N.
.
